Pliant Therapeutics (NASDAQ:PLRX) Posts Earnings Results, Misses Estimates By $0.02 EPS

Pliant Therapeutics (NASDAQ:PLRX) announced its quarterly earnings results on Thursday. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.02), FiscalAI reports.

Pliant Therapeutics Stock Performance

NASDAQ PLRX traded down $0.04 on Thursday, hitting $0.74. The stock had a trading volume of 525,309 shares, compared to its average volume of 548,172. The firm has a 50-day moving average of $0.98 and a 200-day moving average of $1.14. Pliant Therapeutics has a 52-week low of $0.73 and a 52-week high of $1.80. The company has a market capitalization of $45.82 million, a price-to-earnings ratio of -0.50 and a beta of 1.36.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on PLRX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pliant Therapeutics in a research note on Thursday, October 15th. Wall Street Zen downgraded Pliant Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 7th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $3.00.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for fibrotic diseases. The company’s research is centered on integrin biology, a field involving proteins that regulate cell communication and tissue remodeling. Pliant aims to develop medicines that address the underlying processes that drive fibrosis in organs such as the lungs and liver. Pliant’s lead investigational product is bexotegrast, an oral, selective inhibitor of the integrins αvβ1 and αvβ6.